

established a schedule for the final phase of the antidumping duty investigations (89 FR 91423, November 19, 2024). On March 19, 2025, counsel for Eastman Chemical Company (“Eastman”) and counsel for BASF Corporation (“BASF”) filed requests to appear at the hearing. No other parties submitted a request to appear at the hearing. On March 20, 2025, counsel for Eastman filed a request that the Commission cancel the scheduled hearing for these investigations and withdrew its request to appear at the hearing. On March 20, 2025, counsel for BASF withdrew its request to appear at the hearing. Counsel indicated a willingness to respond to any Commission questions in lieu of an actual hearing. Consequently, the public hearing in connection with these investigations, scheduled to begin at 9:30 a.m. on Tuesday, March 25, 2025, is cancelled. Parties to these investigations should respond to any written questions posed by the Commission in their posthearing briefs, which are due to be filed on April 1, 2025.

For further information concerning these investigations see the Commission’s notice cited above and the Commission’s Rules of Practice and Procedure, part 201, subparts A and B (19 CFR part 201), and part 207, subparts A, D, E, and F (19 CFR part 207).

*Authority:* These investigations are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to § 207.21 of the Commission’s rules.

By order of the Commission.  
Issued: March 24, 2025.

**Lisa Barton,**

*Secretary to the Commission.*

[FR Doc. 2025–05271 Filed 3–26–25; 8:45 am]

**BILLING CODE 7020–02–P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA–1526]

**Bulk Manufacturer of Controlled Substances Application; Promega Corporation**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Promega Corporation has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to

**SUPPLEMENTARY INFORMATION** listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before May 27, 2025. Such persons may also file a written request for a hearing on the application on or before May 27, 2025.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on February 26, 2025, Promega Corporation, 3075 Sub Zero Parkway, Fitchburg, Wisconsin 53719, applied to be registered as bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Psilocybin .....	7437	I
Psilocyn .....	7438	I

The company plans to bulk manufacture the listed controlled substances as Active Pharmaceutical Ingredients (API) for sale to its customers. No other activities for these drug codes are authorized for this registration.

**Matthew Strait,**

*Deputy Assistant Administrator.*

[FR Doc. 2025–05283 Filed 3–26–25; 8:45 am]

**BILLING CODE P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. 25–19]

**Willard J. Davis, D.O.; Decision and Order**

On November 13, 2024, the Drug Enforcement Administration (DEA or

Government) issued an Order to Show Cause (OSC) to Willard J. Davis, D.O., of Round Rock, Texas (Respondent). OSC, at 1, 4. The OSC proposed the revocation of Respondent’s DEA Certificate of Registration No. BD9134254, alleging that Respondent’s DEA registration should be revoked because Respondent is “without authority to handle controlled substances in the State of Texas, the state in which [he is] registered with DEA.” *Id.* at 2 (citing 21 U.S.C. 824(a)(3)).

On December 10, 2024 Respondent filed a request for a hearing. On December 30, 2024, the Government filed a Motion for Summary Disposition, which Respondent opposed. On January 23, 2025, Administrative Law Judge Teresa A. Wallbaum (the ALJ) granted the Government’s Motion for Summary Disposition and recommended the revocation of Respondent’s registration, finding that because Respondent lacks state authority to handle controlled substances in Texas, the state in which he is registered with DEA, “[t]here is no genuine issue of material fact in this case.” Order Granting the Government’s Motion for Summary Disposition, and Recommended Rulings, Findings of Fact, Conclusions of Law, and Decision of the Administrative Law Judge (RD), at 6. Respondent did not file exceptions to the RD.

Having reviewed the entire record, the Agency adopts and hereby incorporates by reference the entirety of the ALJ’s rulings, findings of fact, conclusions of law, and recommended sanction as found in the RD and summarizes and expands upon portions thereof herein.

**Findings of Fact**

On May 16, 2024, the Texas Medical Board suspended Respondent’s Texas medical license. RD, at 3.<sup>1</sup> According to Texas online records, of which the Agency takes official notice, Respondent’s Texas medical license remains suspended.<sup>2</sup> Texas Medical Board Healthcare Provider Search, <https://profile.tmb.state.tx.us> (last visited date of signature of this Order).

Accordingly, the Agency finds that Respondent is not currently licensed to

<sup>1</sup> See also Government’s Notice of Filing of Evidence and Motion for Summary Disposition, Exhibit 1, at 3–6.

<sup>2</sup> Under the Administrative Procedure Act, an agency “may take official notice of facts at any stage in a proceeding—even in the final decision.” United States Department of Justice, Attorney General’s Manual on the Administrative Procedure Act 80 (1947) (Wm. W. Gaunt & Sons, Inc., Reprint 1979).